BLUEPRINT MEDICINES ($BPMC) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.74 per share, missing estimates of -$0.54 by $0.20. The company also reported revenue of $149,410,000, missing estimates of $158,557,878 by $-9,147,878.
You can see Quiver Quantitative's $BPMC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BLUEPRINT MEDICINES Insider Trading Activity
BLUEPRINT MEDICINES insiders have traded $BPMC stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.
Here’s a breakdown of recent trading of $BPMC stock by insiders over the last 6 months:
- JEFFREY W. ALBERS has made 0 purchases and 12 sales selling 53,427 shares for an estimated $5,199,046.
- LONNEL COATS has made 0 purchases and 4 sales selling 19,824 shares for an estimated $1,869,657.
- KATE HAVILAND (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 5 sales selling 19,950 shares for an estimated $1,820,920.
- CHRISTINA ROSSI (CHIEF OPERATING OFFICER) has made 0 purchases and 10 sales selling 17,865 shares for an estimated $1,693,990.
- L. BECKER HEWES (CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 10,095 shares for an estimated $890,638.
- ARIEL HURLEY (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 9 sales selling 8,598 shares for an estimated $809,051.
- FOUAD NAMOUNI (PRESIDENT, R & D) sold 6,489 shares for an estimated $576,223
- MICHAEL LANDSITTEL (CHIEF FINANCIAL OFFICER) sold 5,284 shares for an estimated $469,219
- TRACEY L MCCAIN (EVP AND CHIEF LEGAL OFFICER) sold 5,262 shares for an estimated $467,265
- DEBRA DURSO-BUMPUS (CHIEF PEOPLE OFFICER) sold 5,157 shares for an estimated $457,941
- PHILINA LEE (CHIEF COMMERCIAL OFFICER) sold 3,733 shares for an estimated $331,490
- PERCY H. CARTER (CHIEF SCIENTIFIC OFFICER) sold 3,530 shares for an estimated $313,464
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BLUEPRINT MEDICINES Hedge Fund Activity
We have seen 199 institutional investors add shares of BLUEPRINT MEDICINES stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 2,269,092 shares (-50.2%) from their portfolio in Q4 2024, for an estimated $197,910,204
- AVORO CAPITAL ADVISORS LLC added 1,185,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $103,355,700
- LORD, ABBETT & CO. LLC removed 843,147 shares (-71.6%) from their portfolio in Q4 2024, for an estimated $73,539,281
- CITADEL ADVISORS LLC added 572,102 shares (+734.8%) to their portfolio in Q4 2024, for an estimated $49,898,736
- EVENTIDE ASSET MANAGEMENT, LLC added 513,581 shares (+147.3%) to their portfolio in Q4 2024, for an estimated $44,794,534
- MAN GROUP PLC removed 414,697 shares (-80.0%) from their portfolio in Q4 2024, for an estimated $36,169,872
- JENNISON ASSOCIATES LLC added 360,208 shares (+inf%) to their portfolio in Q4 2024, for an estimated $31,417,341
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BLUEPRINT MEDICINES Analyst Ratings
Wall Street analysts have issued reports on $BPMC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Outperform" rating on 03/07/2025
- Citigroup issued a "Buy" rating on 11/05/2024
To track analyst ratings and price targets for BLUEPRINT MEDICINES, check out Quiver Quantitative's $BPMC forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
